FierceBiotechOriginal article
{"a":[{"_":"Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision","$":{"href":"/biotech/zealand-sells-its-rights-takedas-blood-cancer-drug-100m-ahead-fda-decision","hreflang":"en"}}]}
RegulatoryrusfertidePositive
AI Analysis
Summary
Zealand Pharma sold its rights to Takeda and Protagonist Therapeutics' blood cancer drug rusfertide to Takeda for $100 million ahead of an FDA approval decision.
Outcome Details
FDA approval decision pending
Importance:6/10
Sentiment:
0.30
rights saleFDA approval pendingblood cancerpartnership
Read the original article
Published by FierceBiotech on August 13, 2026 5:06 AM